Clinical Trial: Mycophenolate Mofetil in Membranous Nephropathy
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study
Brief Summary:
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects.
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.
Detailed Summary:
Sponsor: Radboud University
Current Primary Outcome:
- renal function (serum creatinine)
- proteinuria
Original Primary Outcome:
- - renal function (serum creatinine)
- - proteinuria
Current Secondary Outcome:
- side effects
- relapse rate
Original Secondary Outcome:
- - side effects
- - relapse rate
Information By: Radboud University
Dates:
Date Received: August 25, 2005
Date Started: May 2002
Date Completion:
Last Updated: December 5, 2005
Last Verified: August 2005